GPG-NH₂ is an experimental anti-HIV drug which blocks formation of the virus capsid protein. This tripeptide has demonstrated anti-HIV activity in test-tube studies and an early safety and efficacy study of GPG-NH₂ in 15 men has been conducted.

The drug was administered orally for two weeks. Six participants underwent a dose escalation while the remaining nine received a consistent dose. Median viral load reduction amongst the nine on the steady dose was 0.4 log with two men experiencing a one log drop. One person developed rash.

Further studies are planned.

References

Pehrson PO et al. An initial safety and efficacy clinical trial of GPG-NH₂, a tripeptide with a new antiretroviral mode of action. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P4, 2000. AIDS 14(supp 4):S17, 2000.